Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
437.4 INR | +0.84% | +0.77% | +1.69% |
09:49am | Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion | RE |
25/04 | Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 121.83 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.69% | 2.8B | C- | ||
+31.21% | 588B | B | ||
-3.42% | 364B | C+ | ||
+18.02% | 326B | B- | ||
+4.27% | 285B | C+ | ||
+14.76% | 239B | B+ | ||
+10.18% | 210B | B- | ||
-6.91% | 200B | A+ | ||
+8.12% | 167B | C+ | ||
-1.42% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAURUSLABS Stock
- Ratings Laurus Labs Limited